US Oxycodone franchise restructure and Doryx re-launch
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA UPDATE
Takes control of US Oxycodone product franchise from Mylan
Doryx re-launch underway with 60+ person sales team in place
4 May 2015, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) today announced
that it has finalised an agreement with Mylan, Inc to end its distribution of Oxycodone products
(Oxycodone tablet, Oxycodone/APAP tablet and Oxycodone/Aspirin tablet) in the United States
from 1 May 2015.
Mayne Pharma has begun marketing and shipping the Oxycodone products under its own label
and will now control the manufacture, marketing and distribution of these products, which
together participate in markets worth more than US$1 billion according to IMS Health. The
restructuring of this legacy third party arrangement will be immediately accretive to earnings.
Furthermore, the Company has also taken-back the Methamphetamine tablet distribution rights
in April 2015 from Mylan and has commenced shipments into the trade.
Mayne Pharma’s CEO, Mr Scott Richards said “The launch of the Oxycodone products represents
the largest generic in-market opportunity for our business today and we are confident we can
improve the performance of these products under our control. Both Methamphetamine and
Oxycodone are key product franchises and the launch of these products under the Mayne
Pharma label is in-line with the Company’s stated strategy to maximise its US retail generic
portfolio through controlling the manufacture, distribution and sales and marketing of key
franchises.”
Doryx re-launch by Mayne Pharma
The Company has completed the establishment of its US Specialty Brands Division responsible
for the marketing and distribution of branded products in the US following the acquisition of the
Doryx assets in February 2015.
The transition period with Actavis has now ended, and the company has immediately
commenced shipment of Doryx tablets in Mayne Pharma livery to the trade. The company has
also completed the recruitment and training of a field sales team of more than 60 personnel to
schedule, many of whom have previous Doryx promotion experience. From today this new
dedicated sales team is in territory promoting the benefits of Doryx to dermatologists.
Mayne Pharma’s CEO, Mr Scott Richards said “It is pleasing to report we have met all the
planned deadlines for Doryx that were announced on the 10 February 2015. The acquisition of
Doryx and the establishment of the new US Specialty Brands Division enables Mayne Pharma to
now control the drug’s entire value chain from development, manufacture, distribution through
to marketing. We believe Doryx is differentiated from other products in this category through its
Page 1
ASX Announcement
unique drug delivery formulation. The launch of Doryx represents the first specialty brand
product we have brought to market in the United States and we expect to commercialise
complementary product innovations over the coming years in dermatology and other specialty
therapeutic areas utilising the Company’s internal pipeline or via targeted in-licensing and/or
product acquisitions.”
For further information contact:
Scott Richards
+61 8 8209 2410
Lisa Pendlebury
+61 419 548 434, lisa.pendlebury@maynepharma.com
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops and manufactures
branded and generic products, which it distributes globally; either directly or through distribution partners
and also provides contract development and manufacturing services.
Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery
systems and these technologies have been successfully commercialised in numerous products that have
been marketed around the world.
Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and
Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds,
controlled substances, modified release products and inherently unstable compounds.
Page 2
Share your feedback
Discover